Amneal Pharmaceuticals, Inc. vs ACADIA Pharmaceuticals Inc.: Examining Key Revenue Metrics

Pharmaceutical Giants: A Decade of Revenue Growth

__timestampACADIA Pharmaceuticals Inc.Amneal Pharmaceuticals, Inc.
Wednesday, January 1, 2014120000785623000
Thursday, January 1, 201561000866280000
Friday, January 1, 2016173310001018225000
Sunday, January 1, 20171249010001033654000
Monday, January 1, 20182238070001662991000
Tuesday, January 1, 20193390760001626373000
Wednesday, January 1, 20204417550001992523000
Friday, January 1, 20214841450002093669000
Saturday, January 1, 20225172350002212304000
Sunday, January 1, 20237264370002393607000
Loading chart...

Cracking the code

A Tale of Two Pharmaceuticals: Revenue Growth from 2014 to 2023

In the competitive landscape of pharmaceuticals, Amneal Pharmaceuticals, Inc. and ACADIA Pharmaceuticals Inc. have showcased distinct revenue trajectories over the past decade. From 2014 to 2023, Amneal Pharmaceuticals has consistently outperformed ACADIA, with revenues peaking at approximately $2.4 billion in 2023, marking a robust growth of over 200% since 2014. In contrast, ACADIA Pharmaceuticals, while starting with a modest revenue of $61,000 in 2015, has demonstrated impressive growth, reaching around $726 million by 2023, a staggering increase of over 11,000%.

This period highlights Amneal's steady dominance in the market, while ACADIA's exponential growth reflects its strategic advancements and market penetration. The data underscores the dynamic nature of the pharmaceutical industry, where innovation and strategic positioning can lead to significant financial gains.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025